Plant Name: Trifolium pratense
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; OPRD1; | |
| GPR35; | |
| TDP1; RECQL; BLM; CDA; TK1; HSD17B1; AKR1B1; HSD17B2; AKR1B10; NQO1; ALDH1A1; ALOX15; TNKS; TNKS2; AOX1; | |
| MGAM; | |
| TRPA1; | |
| ABL1; MAPK1; EGFR; KIT; | |
| CA2; CA1; CA12; CA9; CA7; CA14; CA3; CA5B; CA5A; CA4; CA6; | |
| PPARA; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| MAOA; PTGS1; ALDH2; XDH; | |
| PCSK7; | |
| CASP1; CASP7; | |
| TP53; NFKB1; HIF1A; | |
| ABCG2; | |
| SLC28A3; SLC28A1; SLCO1B3; SLCO1B1; | |
| RAB9A; NPC1; LMNA; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | NQO1 | Quinone reductase 1) | P15559 | CHEMBL3623 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | KIT | Stem cell growth factor receptor | P10721 | CHEMBL1936 |
| Serine protease | PCSK7 | Subtilisin/kexin type 7 | Q16549 | CHEMBL2232 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.785E-12 | 5.437E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.941E-12 | 5.437E-09 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CDA, ESR1, ESR2, ESRRA, ESRRB, PPARA, TK1, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.091E-12 | 1.320E-08 | ALOX15, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, TBXAS1, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.157E-10 | 1.008E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.992E-10 | 1.606E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.572E-10 | 4.616E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.068E-09 | 4.592E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.491E-08 | 6.627E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.105E-08 | 8.388E-06 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.806E-08 | 2.390E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.806E-08 | 2.390E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 9.486E-08 | 3.227E-05 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.665E-07 | 5.035E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.941E-07 | 1.073E-04 | ABL1, BLM, CASP7, CYP1A1, CYP1B1, EGFR, ESR1, MAPK1, NFKB1, NPC1 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.210E-06 | 5.120E-04 | ABCG2, ABL1, CA12, CA2, CA7, EGFR, ESR1, GPR35, HIF1A, MAPK1, TP53, TRPA1 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 3.453E-06 | 7.750E-04 | BLM, RECQL, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.049E-06 | 8.817E-04 | CA2, CA4, CA9, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 5.965E-06 | 1.237E-03 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1, TNKS, TNKS2, TRPA1 |
| MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 8.342E-06 | 1.698E-03 | AKR1B1, AKR1B10, AOX1, HSD17B1, HSD17B2, XDH |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 9.130E-06 | 1.841E-03 | ABCG2, AOX1, BLM, CASP1, CDA, EGFR, ESR1, ESR2, KIT, MAPK1, MAPT, NFKB1, NQO1, RAB9A, TK1, TP53, TRPA1, XDH |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 9.694E-06 | 1.937E-03 | ABL1, AKR1B1, BLM, CASP7, EGFR, MAPK1, NFKB1, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 1.221E-05 | 2.273E-03 | AOX1, XDH |
| BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 1.221E-05 | 2.273E-03 | CDA, MAPK1 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.221E-05 | 2.273E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.221E-05 | 2.273E-03 | SLC28A1, SLC28A3 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.656E-05 | 2.956E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HSD17B2, PTGS1, RAB9A, SLC28A3, TBXAS1 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.739E-05 | 4.694E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 3.655E-05 | 5.566E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.655E-05 | 5.566E-03 | CYP2D6, CYP3A4 |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 3.655E-05 | 5.566E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.655E-05 | 5.566E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 3.655E-05 | 5.566E-03 | SLC28A1, SLC28A3 |
| BP | GO:0065007; biological regulation | GO:0051882; mitochondrial depolarization | 3.655E-05 | 5.566E-03 | ABL1, CASP1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.655E-05 | 5.566E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 3.922E-05 | 5.849E-03 | AKR1B1, ALDH2, AOX1, CYP1A2, XDH |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 4.557E-05 | 6.616E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:0034308; primary alcohol metabolic process | 5.164E-05 | 7.388E-03 | AKR1B10, ALDH1A1, ALDH2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.302E-05 | 8.707E-03 | ABL1, AKR1B1, CYP1B1, NQO1 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 6.302E-05 | 8.707E-03 | AKR1B1, CYP3A4, HSD17B1, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.026E-05 | 9.623E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.294E-05 | 9.625E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.294E-05 | 9.625E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.294E-05 | 9.625E-03 | ESR1, ESR2 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 7.585E-05 | 9.866E-03 | CYP1A2, EGFR, ESR1, ESRRA, NQO1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.933E-25 | 1.292E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.081E-18 | 2.237E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.462E-17 | 1.508E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.650E-24 | 6.425E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.804E-09 | 1.901E-07 | CDA; MGAM; MAOA; ALOX15; AKR1B1; CYP2C19; CYP3A4; PTGS1; CYP2C9; AKR1B10; ALDH2; HSD17B1; TBXAS1; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; AOX1; TK1; XDH |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.321E-09 | 1.901E-07 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.493E-09 | 1.901E-07 | CYP2C9; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.343E-08 | 1.279E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.046E-07 | 2.300E-06 | CYP2C9; CYP2D6; MAOA; ALOX15; MAPK1; CYP2C19; PTGS1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.700E-08 | 2.187E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.755E-07 | 3.432E-06 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.361E-08 | 1.279E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.525E-07 | 6.204E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.179E-06 | 3.486E-05 | CYP2C9; ALOX15; TBXAS1; CYP2C19; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.210E-06 | 4.707E-05 | KIT; MAPK1; TP53; HIF1A; EGFR |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.282E-06 | 5.797E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.502E-05 | 2.935E-04 | HSD17B1; HSD17B2; CYP1A1; CYP1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.515E-05 | 8.266E-04 | MAPK1; TP53; EGFR; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.791E-05 | 2.251E-04 | CDA; TK1; CYP3A4; XDH |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.985E-05 | 9.302E-04 | MAPK1; PPARA; TP53; EGFR; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.144E-04 | 9.592E-04 | CASP7; LMNA; MAPK1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.056E-04 | 9.592E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.115E-04 | 9.592E-04 | ABL1; MAPK1; TP53; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.941E-04 | 2.477E-03 | KIT; ABL1; MAPK1; HIF1A; TP53; EGFR; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.401E-04 | 1.744E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.608E-04 | 2.381E-03 | MAPK1; ESR1; EGFR; ESR2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.239E-04 | 9.909E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.155E-04 | 3.024E-03 | ABL1; CYP1B1; MAPK1; TP53; EGFR; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.364E-04 | 3.613E-03 | MAPK1; TP53; HIF1A; ESR1; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.195E-04 | 2.546E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.008E-04 | 3.753E-03 | MAPK1; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.464E-04 | 3.753E-03 | ABL1; MAPK1; TP53; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.051E-03 | 4.578E-03 | KIT; ABL1; MAPK1; EGFR; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.464E-04 | 3.753E-03 | OPRD1; MAPK1; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.756E-03 | 7.024E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.653E-04 | 2.381E-03 | MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.374E-04 | 3.753E-03 | MAPK1; TP53; EGFR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 9.160E-04 | 4.353E-03 | MAPK1; TP53; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.645E-04 | 4.353E-03 | KIT; MAPK1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.412E-03 | 5.780E-03 | MAPK1; TP53; EGFR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.066E-03 | 1.941E-02 | KIT; MAPK1; TP53; EGFR; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.715E-03 | 1.596E-02 | MAPK1; PPARA; NFKB1; TSHR |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.429E-04 | 1.094E-03 | MGAM; AKR1B10; AKR1B1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 8.690E-04 | 4.249E-03 | CASP7; CASP1; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.821E-03 | 7.123E-03 | MAPK1; TP53; EGFR |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.477E-04 | 1.744E-03 | AKR1B10; ALDH2; AKR1B1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.249E-03 | 1.167E-02 | ABL1; MAPK1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.939E-03 | 1.640E-02 | MAPK1; HIF1A; EGFR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.259E-03 | 1.946E-02 | CASP7; MAPK1; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.066E-03 | 4.578E-03 | AKR1B10; ALDH2; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 9.645E-04 | 4.353E-03 | CASP1; MAPK1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.319E-03 | 2.524E-02 | TBXAS1; MAPK1; PTGS1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.145E-03 | 1.153E-02 | CASP1; MAPK1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.117E-02 | 3.333E-02 | RAB9A; TP53; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.412E-03 | 5.780E-03 | ABL1; MAPK1; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.303E-02 | 3.587E-02 | KIT; MAPK1; EGFR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.352E-02 | 3.660E-02 | MAPK1; TP53; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.478E-02 | 3.943E-02 | CASP7; PPARA; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.959E-02 | 4.926E-02 | CASP7; MAPK1; MAPT |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.776E-02 | 4.596E-02 | MAPK1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.559E-02 | 4.094E-02 | TSHR; PTGS1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.889E-02 | 4.819E-02 | MAPK1; TP53 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 2.005E-02 | 4.945E-02 | CASP1; NFKB1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.208E-02 | 3.487E-02 | MAOA; NFKB1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 1.256E-02 | 3.566E-02 | ALDH2; MAOA |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 1.162E-02 | 3.408E-02 | ALDH2; AOX1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 1.305E-02 | 3.587E-02 | CASP1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.358E-03 | 1.504E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 3.784E-03 | 1.332E-02 | MAPK1; EGFR |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 6.304E-03 | 1.946E-02 | MAOA; AOX1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 5.290E-03 | 1.724E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.752E-03 | 1.053E-02 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 2.995E-03 | 1.122E-02 | ALDH2; MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.132E-04 | 9.592E-04 | CYP1A2; XDH |
| hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 2.023E-02 | 4.945E-02 | AOX1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; TK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; KIT |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; EGFR; EGFR; EGFR; ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; MAOA; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1; TK1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; AKR1B1; CASP1; ESRRA |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; EGFR; ESR1; TK1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; TBXAS1; MGAM |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA1; CA9; ABL1; MAPK1; NFKB1; EGFR; ESR1; ESR1; KIT; HIF1A; TK1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; ABL1 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4; MAOA |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; MAOA; ALDH2 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; ABL1; MAPK1; EGFR; KIT; HIF1A; CDA; TK1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; TRPA1; OPRD1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TK1 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| NA: NA | Edema | NA | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; ESR1; ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; EGFR; HIF1A |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; TP53; EGFR; EGFR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | NQO1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |